Strategic partnerships Evenamide collaboration with EA Pharma for Japan and Asia and Myung In Pharm for South Korea indicates a proven partner-friendly model and regional expansion opportunities that can be leveraged to proximate market access and co-development deals in additional territories.

Clinical momentum ENIGMA-TRS and ENIGMA-TRS 2 Phase III programs, along with a growing body of efficacy and safety data, create a strong value proposition for partnering in global regulatory discussions and potential accelerated access discussions in schizophrenia treatment.

Commercial footprint Xadago/safinamide is already marketed across multiple major markets with existing distribution partners, suggesting near-term revenue streams and a blueprint for future co-promotion or rights sales in additional regions.

Funding runway Significant funding raised and ongoing financing in Europe supports late-stage development and potential commercialization investments, enabling strategic BD opportunities, licensing deals, and milestone-driven partnerships.

Leadership transition Upcoming AGM with board changes and leadership nominations present a window to align on strategic priorities, potentially opening conversations around new BD leadership, alliance policies, and targeted collaboration opportunities.